Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

VYGR

Voyager Therapeutics (VYGR)

Voyager Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VYGR
FechaHoraFuenteTítuloSímboloCompañía
16/09/202406:00GlobeNewswire Inc.Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate SelectedNASDAQ:VYGRVoyager Therapeutics Inc
05/09/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYGRVoyager Therapeutics Inc
05/09/202407:00GlobeNewswire Inc.Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14NASDAQ:VYGRVoyager Therapeutics Inc
29/08/202415:01GlobeNewswire Inc.Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VYGRVoyager Therapeutics Inc
29/08/202406:00GlobeNewswire Inc.Voyager Therapeutics to Present at Multiple Upcoming Investor ConferencesNASDAQ:VYGRVoyager Therapeutics Inc
07/08/202406:00GlobeNewswire Inc.Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company ShowcaseNASDAQ:VYGRVoyager Therapeutics Inc
06/08/202415:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VYGRVoyager Therapeutics Inc
06/08/202415:01GlobeNewswire Inc.Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
30/07/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Second Quarter 2024 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
09/07/202415:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
09/07/202415:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
13/06/202415:01GlobeNewswire Inc.Voyager Therapeutics to Present at Multiple Virtual Investor ConferencesNASDAQ:VYGRVoyager Therapeutics Inc
13/06/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial OfficerNASDAQ:VYGRVoyager Therapeutics Inc
16/05/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s DiseaseNASDAQ:VYGRVoyager Therapeutics Inc
13/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VYGRVoyager Therapeutics Inc
13/05/202415:01GlobeNewswire Inc.Voyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
08/05/202405:00GlobeNewswire Inc.Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingNASDAQ:VYGRVoyager Therapeutics Inc
06/05/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
22/04/202415:30GlobeNewswire Inc.Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingNASDAQ:VYGRVoyager Therapeutics Inc
16/04/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
13/03/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerNASDAQ:VYGRVoyager Therapeutics Inc
28/02/202415:01GlobeNewswire Inc.Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
26/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202414:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
20/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late ResearchNASDAQ:VYGRVoyager Therapeutics Inc
07/02/202406:00GlobeNewswire Inc.Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
17/01/202415:20Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VYGRVoyager Therapeutics Inc
08/01/202415:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VYGRVoyager Therapeutics Inc
04/01/202421:45GlobeNewswire Inc.Voyager Therapeutics Announces Pricing of Public OfferingNASDAQ:VYGRVoyager Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VYGR